An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-Blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2010
At a glance
- Drugs Dasabuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 03 Sep 2009 Actual patient number (34) added as reported by ClinicalTrials.gov.
- 03 Sep 2009 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
- 03 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov